STAT3 and prostate carcinoma: In the stratified analysis by tumor types, STAT3 expression was associated with worse 3-year OS of gastric cancer (OR = 4.06, 95% CI = 1.86 to 8.89, P = 0.0004), lung cancer (OR = 2.22, 95% CI = 1.31 to 3.77, P = 0.003), gliomas (OR = 4.10, 95% CI = 1.50 to 11.23, P = 0.006), hepatic cancer (OR = 3.75, 95% CI = 1.71 to 8.21, P = 0.001), osteosarcoma (OR = 3.94, 95% CI = 1.83 to 8.51, P = 0.0005) and prostate cancer (OR = 11.08, 95% CI = 1.24 to 98.96, P = 0.03) (Figure 3).